Appendix
AD7.2.3.3 Efficacy Data for
Study 212
|
Table
AD2 Study 212 Patient
Completion Rates |
||||||||||
|
Treatment Groups |
Number Randomized |
Intent-to- Treat Sample |
Completers at Week [N (%)] |
|||||||
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
|||
|
BUP SR 150 |
146 |
145 |
145 (100%) |
136 (94%) |
133 (92%) |
133 (92%) |
122 (84%) |
118 (81%) |
117 (81%) |
110 (76%) |
|
BUP SR 300 |
144 |
144 |
144 (100%) |
136 (94%) |
131 (91%) |
121 (84%) |
111 (77%) |
104 (72%) |
104 (72%) |
101 (70%) |
|
Placebo |
148 |
145 |
145 (100%) |
140 (97%) |
132 (91%) |
124 (86%) |
117 (81%) |
114 (79%) |
107 (74%) |
100 (69%) |
Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index